Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.

Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Sandhu MS, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Boekholdt SM.

J Am Coll Cardiol. 2010 Sep 14;56(12):946-55. doi: 10.1016/j.jacc.2010.04.048.

2.

Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.

van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, Khaw KT.

Ann Intern Med. 2007 May 1;146(9):640-8.

PMID:
17470832
3.

Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.

Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, Sandhu MS, Jukema JW, Kastelein JJ, Hack CE, Khaw KT.

Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):839-46. Epub 2005 Feb 3.

4.

Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.

Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1788-95. Epub 2007 May 31.

5.

Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.

Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Tsimikas S.

J Lipid Res. 2011 Oct;52(10):1829-36. doi: 10.1194/jlr.M015776. Epub 2011 Aug 5.

6.

Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Taleb A, Witztum JL, Tsimikas S.

Biomark Med. 2011 Oct;5(5):673-94. doi: 10.2217/bmm.11.60. Review.

7.

Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.

van Capelleveen JC, Bernelot Moens SJ, Yang X, Kastelein JJP, Wareham NJ, Zwinderman AH, Stroes ESG, Witztum JL, Hovingh GK, Khaw KT, Boekholdt SM, Tsimikas S.

Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1206-1212. doi: 10.1161/ATVBAHA.117.309007. Epub 2017 May 4.

PMID:
28473441
8.

Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.

Nsaibia MJ, Mahmut A, Boulanger MC, Arsenault BJ, Bouchareb R, Simard S, Witztum JL, Clavel MA, Pibarot P, Bossé Y, Tsimikas S, Mathieu P.

J Intern Med. 2016 Nov;280(5):509-517. doi: 10.1111/joim.12519. Epub 2016 May 30.

PMID:
27237700
9.

Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study.

Rana JS, Cote M, Després JP, Sandhu MS, Talmud PJ, Ninio E, Wareham NJ, Kastelein JJ, Zwinderman AH, Khaw KT, Boekholdt SM.

Heart. 2009 Oct;95(20):1682-7. doi: 10.1136/hrt.2009.170134. Epub 2009 Jul 8.

PMID:
19587389
10.

C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study.

van Wijk DF, Boekholdt SM, Wareham NJ, Ahmadi-Abhari S, Kastelein JJ, Stroes ES, Khaw KT.

Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2888-94. doi: 10.1161/ATVBAHA.113.301736. Epub 2013 Sep 26.

11.

Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.

Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM.

J Am Coll Cardiol. 2007 Jul 10;50(2):159-65. Epub 2007 Jun 21.

12.

Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.

Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB.

N Engl J Med. 2005 Jul 7;353(1):46-57.

13.

Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease.

Muller O, Ntalianis A, Wijns W, Delrue L, Dierickx K, Auer R, Rodondi N, Mangiacapra F, Trana C, Hamilos M, Valentin E, De Bruyne B, Barbato E, Bartunek J.

J Cardiovasc Transl Res. 2013 Aug;6(4):536-44. doi: 10.1007/s12265-013-9468-x. Epub 2013 May 14.

PMID:
23670230
14.

Apolipoprotein A-II is inversely associated with risk of future coronary artery disease.

Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, Stroes ES, Otvos JD, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM.

Circulation. 2007 Oct 30;116(18):2029-35. Epub 2007 Oct 8.

15.

Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).

Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P, Brilakis E, Kornman KS, Witztum JL.

J Am Coll Cardiol. 2014 May 6;63(17):1724-34. doi: 10.1016/j.jacc.2013.12.030. Epub 2014 Feb 12.

16.

Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.

Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Pomilla C, Wareham NJ, Khaw KT, Boekholdt SM, Sandhu MS.

Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):3058-65. doi: 10.1161/ATVBAHA.112.255521. Epub 2012 Oct 11.

17.

Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study.

Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1177-83. Epub 2007 Feb 15.

18.

Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study).

Arsenault BJ, Kohli P, Lambert G, DeMicco DA, Laskey R, Messig MM, Kastelein JJ, Waters DD.

Am J Cardiol. 2016 Aug 15;118(4):494-8. doi: 10.1016/j.amjcard.2016.05.044. Epub 2016 May 29.

PMID:
27328952
19.

All-cause mortality and competing risks of fatal and nonfatal vascular events in the Italian longitudinal study on aging: impact of lipoprotein(a).

Solfrizzi V, Colacicco AM, D'Introno A, Capurso C, Chirico M, Frisardi V, Cacciapaglia M, Vendemiale G, Capurso A, Panza F.

Rejuvenation Res. 2009 Dec;12(6):395-402. doi: 10.1089/rej.2009.0865.

PMID:
20014954
20.

Oxidation-specific biomarkers and risk of peripheral artery disease.

Bertoia ML, Pai JK, Lee JH, Taleb A, Joosten MM, Mittleman MA, Yang X, Witztum JL, Rimm EB, Tsimikas S, Mukamal KJ.

J Am Coll Cardiol. 2013 May 28;61(21):2169-79. doi: 10.1016/j.jacc.2013.02.047. Epub 2013 Mar 26.

Supplemental Content

Support Center